EVOKE PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.54 USD | +0.88% |
|
+2.08% | -48.59% |
| May. 28 | Evoke Pharma, Inc. Appoints Mark A. Kowieski as Chief Financial Officer | CI |
| May. 14 | Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 39.26 | 68.09 | 17.96 | 8.959 | 3.511 | 4.643 | - | - |
| Enterprise Value (EV) 1 | 39.26 | 68.09 | 17.96 | 8.959 | 3.511 | 4.643 | 4.643 | 4.643 |
| P/E ratio | -5.06 x | -4.96 x | -2.04 x | -1.02 x | -0.45 x | -6.75 x | 5.4 x | 1.93 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 2,958 x | 11.1 x | 3.57 x | 0.68 x | 0.34 x | 0.21 x | 0.14 x |
| EV / Revenue | - | 2,958 x | 11.1 x | 3.57 x | 0.68 x | 0.34 x | 0.21 x | 0.14 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,019 | 2,199 | 2,721 | 3,343 | 3,343 | 8,597 | - | - |
| Reference price 2 | 19.44 | 30.96 | 6.600 | 2.680 | 1.050 | 0.5400 | 0.5400 | 0.5400 |
| Announcement Date | 3/12/20 | 3/11/21 | 3/8/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.023 | 1.618 | 2.509 | 5.181 | 13.68 | 21.9 | 32.03 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.154 | -13.05 | -8.152 | -7.786 | -7.431 | -0.844 | 4.642 | 12.64 |
| Operating Margin | - | -56,678.32% | -503.79% | -310.37% | -143.44% | -6.17% | 21.19% | 39.47% |
| Earnings before Tax (EBT) 1 | -7.126 | -13.15 | -8.538 | -8.224 | -7.792 | -1.191 | 4.311 | 12.31 |
| Net income 1 | -7.126 | -13.15 | -8.538 | -8.224 | -7.792 | -1.191 | 3.233 | 9.232 |
| Net margin | - | -57,144.53% | -527.66% | -327.83% | -150.41% | -8.71% | 14.76% | 28.82% |
| EPS 2 | -3.840 | -6.240 | -3.240 | -2.620 | -2.330 | -0.0800 | 0.1000 | 0.2800 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/11/21 | 3/8/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.3606 | 0.4184 | 0.4618 | 0.8321 | 0.7964 | 0.8104 | 1.131 | 1.563 | 1.676 | 1.735 | 2.98 | 4.104 | 4.859 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.547 | -2.051 | -2.113 | -1.913 | -1.71 | -2.155 | -1.784 | -1.603 | -1.888 | -1.501 | -0.511 | 0.284 | 0.884 |
| Operating Margin | -429.14% | -490.26% | -457.48% | -229.85% | -214.7% | -265.93% | -157.72% | -102.6% | -112.65% | -86.5% | -17.15% | 6.92% | 18.19% |
| Earnings before Tax (EBT) 1 | -1.672 | -2.174 | -2.233 | -2.014 | -1.803 | -2.243 | -1.868 | -1.694 | -1.987 | -1.58 | -0.601 | 0.195 | 0.795 |
| Net income 1 | -1.672 | -2.174 | -2.233 | -2.014 | -1.803 | -2.243 | -1.868 | -1.694 | -1.987 | -1.58 | -0.601 | 0.195 | 0.795 |
| Net margin | -463.81% | -519.54% | -483.62% | -242.02% | -226.43% | -276.78% | -165.1% | -108.39% | -118.58% | -91.03% | -20.17% | 4.75% | 16.36% |
| EPS 2 | -0.7200 | -0.8400 | -0.7100 | -0.6000 | -0.5300 | -0.6700 | -0.5600 | -0.5100 | -0.5900 | -0.1700 | -0.0600 | 0.0100 | 0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/8/22 | 5/10/22 | 8/10/22 | 11/9/22 | 3/21/23 | 5/15/23 | 8/10/23 | 11/9/23 | 3/14/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/11/21 | 3/8/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.54
USD
Average target price
7
USD
Spread / Average Target
+1,196.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.59% | 4.64M | |
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B |
- Stock Market
- Equities
- EVOK Stock
- Financials Evoke Pharma, Inc.
